Synonyms: FGFR1:Fc | FP1039 | GSK-3052230 | GSK3052230 | HGS1036
Compound class:
Peptide
Comment: FP-1039 (GSK3052230) is a fusion protein that comprises the extracellular domain of FGF receptor 1c (FGFR1c; to act as a trap for FGF ligands) fused with the Fc region of IgG1. The full peptide sequence is not disclosed in the primary citation [1]. FP-1039 is an oncology lead candidate [1,3].
|
No information available. |
Summary of Clinical Use ![]() |
FP-1039 was progressed into clinical evaluation by Five Prime Therapeutics. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01244438 | Study of FP-1039 in Subjects With Endometrial Cancers | Phase 2 Interventional | Five Prime Therapeutics, Inc. | This study was terminated because no patients with endometrial cancers with qualifying FGFR2-specific mutations could be recruited. | |
NCT01868022 | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | Phase 1 Interventional | GlaxoSmithKline | 2 |